About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
2024 Updates in PV/ET
By
University of Colorado Division of Hematology
FEATURING
Brandon McMahon
By
University of Colorado Division of Hematology
FEATURING
Brandon McMahon
662 views
April 19, 2024
0 Comments
Login to view comments.
Click here to Login
Featured Video
07:44
Incyte
Optimizing the Management of Patients with Polycythemia Vera (PV)
Feat.
P. Bose,
R. Rampal
Featured Video
16:26
Incyte
Effects of a Treatment Option on Hematocrit Control and Spleen Volum…
Feat.
C. Harrison
Related Content
AUTOPLAY
ON
16th International Congress on Myeloproliferative Neoplasms
16th International Congress on Myeloproliferative Neoplasms
Thu, Oct 24, 2024
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
08:44
American Contact Dermatitis Society (ACDS)
What to Do When Patch Testing is Negative?
Feat.
M. Montanez-Wiscovich
24:27
BMFcases
Experts Discuss Pros and Cons of Treatment Approaches in PV
Feat.
T. Bat,
A. Tefferi
22:21
Integrity CE
2024 Updates on Myeloproliferative Neoplasms, PV, and ET
Feat.
A. Tefferi
08:18
Insights from 2023 ASH Annual Meeting
Treatment Strategies for Hematocrit Control in PV
Feat.
A. Zhou
17:05
BMFcases
Diagnosis and Prognosis in PV: Utility of BM Biopsy, Clinical Findin…
Feat.
T. Bat,
A. Tefferi
27:37
Indy Hematology Review
Review of Myeloproliferative Neoplasms
Feat.
A. Tefferi
16:51
Incyte
Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk
Feat.
C. Harrison
21:52
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…
Feat.
D. Tremblay
10:02
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…
Feat.
R. Mesa
05:20
Prithviraj Bose
When to Switch From Hydroxyurea to Ruxolitinib in PV
08:49
BMFcases
Experts Address Clinical Questions in PV: Utility of Aspirin, Rusfer…
Feat.
T. Bat,
A. Tefferi
11:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
2024 Updates in Myeloproliferative Neoplasms
Feat.
E. Hexner
08:11
Krisstina Gowin
Counseling Patients With Newly Diagnosed PV or ET
19:47
Monia Marchetti
CYTO-PV Study: Importance of Hematocrit Control and Early Interventi…
09:27
ASH 2022 Conference Coverage
MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…
Feat.
M. McMullin
13:38
Insights from 2024 EHA Annual Meeting
Top 5 Impactful MPN Abstracts From Summer Conferences
Feat.
P. Bose
16:25
Northwestern Medicine Oncology and Hematology
Diagnosis and Goals of Therapy in PV
Feat.
B. Stein